AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
_07_03_2026_03_50_21_133108.jpg)
NeuroTech International Limited (ASX:NTI) has successfully converted 5 million performance rights into fully paid ordinary shares, increasing its issued capital on the Australian Securities Exchange. This conversion, completed on 21 July 2026, follows shareholder approval granted at the general meeting held in August 2024. Post-conversion, NeuroTech's total quoted ordinary share capital stands at approximately 1.32 billion shares. The conversion was valued at an estimated AUD $0.018 per share based on the closing price on 20 July 2026.
Key Highlights
- On 21 July 2026, NeuroTech International Limited (NTI) converted 5 million performance rights into ordinary fully paid shares.
- The conversion was approved under resolution 2 of the Notice of General Meeting released to the ASX on 9 August 2024.
- Total quoted ordinary share capital increased to 1,322,741,687 shares following the conversion.
- The estimated conversion value was AUD $0.018 per share, based on the 20 July 2026 closing share price.
- NeuroTech retains 30 million unquoted performance rights and 49.5 million unquoted options with varying exercise prices and expiry dates.
Overview of NeuroTech's Capital Structure and Performance Rights Conversion
NeuroTech International Limited, an ASX-listed company specializing in neurotechnology solutions, operates within the rapidly evolving neurotech sector, which serves medical, research, and commercial markets. The company utilizes performance rights as part of its capital management and employee incentive programs.
The recent conversion of 5 million performance rights, previously unquoted securities under the code NTIAAH, into ordinary shares was executed following shareholder approval received in August 2024. This approval authorized the terms and conditions for the performance rights, culminating in the conversion finalized on 21 July 2026. This milestone reflects a key phase in NeuroTech's capital structure strategy as outlined in the original shareholder resolution.
Impact of Performance Rights Conversion on Issued Capital
The conversion has materially increased NeuroTech's issued capital, bringing the total ordinary fully paid shares quoted on the ASX to 1,322,741,687. The addition of 5 million shares stems from the performance rights realization approved by shareholders in August 2024. No cash consideration was involved; the conversion fulfilled the original issuance terms of the performance rights.
NeuroTech's unquoted capital remains significant, with 30 million unquoted performance rights still outstanding in the NTIAAH class, indicating potential future conversions. The company also holds 49.5 million unquoted options across six classes, featuring exercise prices from AUD $0.02 to AUD $0.18 and expiry dates ranging from July 2028 to February 2030. This diverse option portfolio supports flexible future capital management and equity-based incentives.
Valuation and Share Price at Conversion Date
The conversion valuation was estimated at AUD $0.018 per share, based on the closing price on 20 July 2026, the business day preceding the conversion date. NeuroTech clarified that this figure was provided solely for the ASX quotation application and should not be interpreted as a comprehensive valuation. Such disclaimers are standard in ASX disclosures, recognizing that a single-day closing price may not reflect intrinsic value.
This per-share estimate corresponds to an aggregate notional value of approximately AUD $90,000 for the 5 million shares converted. Investors should note that this historical valuation was used for regulatory reporting and does not predict future share price movements or trading values.
Shareholder Approval and Corporate Governance
The conversion was conducted under a governance framework requiring shareholder approval. NeuroTech's Notice of General Meeting, released on 9 August 2024, included resolution 2 authorizing the issuance and conversion of performance rights. This process ensured shareholder transparency and consent regarding potential dilution and terms prior to granting and converting the rights.
Utilizing performance rights aligns with common practices among ASX-listed technology and life sciences companies, where equity incentives are linked to share price performance and operational milestones. By securing shareholder approval in advance, NeuroTech complied with the Corporations Act 2001 (Cth) and ASX Listing Rules. The conversion completion nearly two years later indicates satisfaction of vesting or exercise conditions.
Outstanding Unquoted Securities and Future Capital Strategy
Post-conversion, NeuroTech retains 30 million unquoted performance rights and 49.5 million unquoted options, which may lead to further share issuance upon vesting or exercise. The options are divided into six classes with exercise prices between AUD $0.02 and AUD $0.18 and expiry dates from July 2028 to February 2030, offering strategic capital management flexibility.
Specifically, 13 million options at AUD $0.02 and 13 million at AUD $0.03 expire on 13 July 2028, while 10 million options each at AUD $0.16 and AUD $0.18 expire on 24 February 2030. Investors should monitor these securities as their exercise or conversion could dilute existing shareholdings unless offset by capital management measures.
Regulatory Compliance and ASX Listing Rules Adherence
The share conversion and quotation application complied with ASX Listing Rules, particularly Appendix 2A governing security quotation post-exercise or conversion. NeuroTech confirmed that the newly issued ordinary shares rank equally with existing shares, ensuring identical economic and voting rights for all shareholders. This parity maintains share registry integrity and market fairness.
The shares were issued without cash consideration, resulting from the conversion of performance rights under an approved incentive plan. This distinction affects disclosure obligations and transaction classification under the Corporations Act. NeuroTech's transparency reduces investor confusion around cash flows or fundraising activities.
Investor Considerations Moving Forward
Investors should track the vesting and exercise schedules of the remaining 30 million unquoted performance rights and 49.5 million unquoted options. Exercise activity, especially for options with exercise prices at AUD $0.02 and AUD $0.03 expiring in July 2028, may signal share price appreciation and potential dilution.
Monitoring future capital raises, acquisitions, or strategic initiatives will provide insight into NeuroTech's equity incentive use and capital management approach. Changes in capital structure or issuance of new convertible securities should be evaluated relative to the company's business strategy and operational milestones. The total shares on issue and dilution effects impact earnings per share and shareholder ownership proportions.
Share Price Context and Market Environment
The conversion price of AUD $0.018 per share, based on 20 July 2026 closing price, serves as a historical valuation benchmark. Immediate market impact was not detailed in the company update. Market responses to dilution events depend on factors including growth outlook, earnings announcements, macroeconomic trends, and sector sentiment. The conversion is primarily a technical capital event rather than a fundamental share price driver.
The addition of 5 million shares marginally increases NeuroTech's float but is unlikely to materially affect liquidity given the existing approximately 1.32 billion shares outstanding. Actual trading prices post-conversion may vary significantly due to company-specific and market factors.
